Leiden University Scholarly Publications

Search results

  • RSS Feed
(1 - 20 of 21)

Pages

WD 0141−675: a case study on how to follow-up astrometric planet candidates around white dwarfs
Near‐infrared phototransistor based on graphene/C60/PbPc heterojunction with tunable bidirectional photoresponse
Exocomets from a solar system perspective
The state of altmetrics
Direct detection of black hole-driven turbulence in the centers of galaxy clusters
A planetesimal orbiting within the debris disc around a white dwarf star
Tweeting Library and Information Science: a socio-topical distance analysis
Evaluating the influence of social media exposure of scholarly articles: Perspectives of social media engagement and click metrics
The state and evolution of Gold Open Access: A country level analysis
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
Identification and Characterization of a Ribose 2 '-O-Methyltransferase Encoded by the Ronivirus Branch of Nidovirales
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
SERUM BIOMARKERS ASSOCIATED WITH CHANGES IN ASDAS AND MRI FOLLOWING TREATMENT OF AS WITH GOLIMUMAB
Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY

Pages